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ABSTRACT 
This paper is aimed at describing the framework in which international trade in medical 
products takes place, and analyzing the determinants of Spanish imports of the cited products 
from OECD countries and China. Regarding the latter, two econometric analyses based on 
the Gravity Model of world trade are performed, concerning 2016 cross-sectional data and 
2007-2017 panel data. Results from these analyses suggest that total Spanish imports of the 
pharmaceutical products and personal protective equipment studied are explained by distinct 
variables. These variables are EU membership, trade competitiveness, number of researchers 
and share of high technology exports of the exporting country. Likewise, certain variables 
determining Spanish imports of various types of pharmaceutical products appear to diverge, 
including the cited regressors, as well as the value of exports of the same products by Spain. 
Moreover, the Gravity Model seems to hold over time for Spanish imports of all the medical 
products considered. 
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1. INTRODUCTION 
International trade has nowadays reached unprecedented levels as a proportion of total world 
production (Krugman et al., 2018). Although trade may adversely affect particular groups 
within nations, it almost always brings mutual benefits to the trading countries, such as 
increasing the variety of goods available to people or bringing down domestic prices. There 
are two main reasons explaining trade among countries: (i) Comparative advantage, as a 
consequence of differences in resources, tastes or technology; and (ii) economies of scale 
that make it profitable for states to specialize in the production of a small number of products 
(Krugman et al., 2018). Regarding economies of scale, they may take the form of internal or 
external. The unitary cost in the former decreases with the size of an individual firm, while 
that in the latter does so with geographical concentration of the industry. The main focus of 
the present study is international trade in pharmaceutical products, being the pharmaceutical 
industry a notable example of internal economies of scale.  
As regards internal economies of scale, increasing returns lead to imperfect competition 
(Krugman et al., 2018). High entry barriers exist in the pharmaceutical sector, as large R&D 
investments are required, while there is little certainty about the final result at the beginning 
of the process of drug development (Priede Bergamini et al., 2009). Therefore, most of the 
firms engaging in those processes are large companies.  
Internal economies of scale create incentives for international specialization and subsequent 
trade and, consequently, production is concentrated among better-performing firms, leading 
to an improvement of the general efficiency of the industry (Krugman et al., 2018). In this 
vein, due to the need of a larger market size so as to cover the high costs incurred by firms 
operating in the sector, international trade in pharmaceutical products is high (Priede 
Bergamini et al., 2009). Based on the data provided by World Trade Organization (2020a), 
world exports of pharmaceutical products in 2019 amounted to $547.69 billion, while 
imports had a value of $566.33 billion.  
Given the importance of international trade in personal protective equipment (PPE) as a 
consequence of the Covid-19 outbreak and, due to the close connection existing between 
these goods and medicines being both part of medical products, they are also included in the 
present analysis. World imports of PPE1 in year 2019 had a value of $131.47 billion, whereas 
exports added up to $139.42 billion in the same year (World Trade Organization, 2020a). 
 
1 As defined by World Trade Organization (2020a).  
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This paper is aimed at (i) describing the context in which international trade in medical 
products takes place, and (ii) analyzing the determinants of Spanish imports of medical 
goods, namely of pharmaceutical products and PPE, from OECD countries and China. An 
econometric analysis concerning 2016 cross-sectional data and 2007-2017 panel data is 
performed for the purpose of the latter. From now on, medical goods will jointly refer to 
medicines and PPE. The analysis is focused on OECD countries and China, since 92.84% 
of Spanish imports of pharmaceutical products and 95.11% of PPE imports by Spain in 2019 
had their origin in this group of countries (DataComex, 2020). 
An econometric analysis seeking to find out the determinants of Spanish exports of medical 
goods to OECD countries and China has also been performed. Nevertheless, given that the 
results obtained do not seem to be consistent with the industry characteristics and trade 
regulation of the products in matter, it has been decided not to include it in the present paper. 
The paper structure is as follows. Firstly, it provides information about the main 
characteristics of the market for pharmaceutical products and of that for PPE in sections 2 
and 3, respectively. Section 4 summarizes the current situation of international trade in 
medical products in the Covid-19 context. Then, an overview of the evolution and main 
trading partners of Spain, as regards its trade in medical goods with the rest of the world, is 
provided in section 5. Section 6 presents an econometric analysis of Spanish imports of 
medical products from OECD countries and China, involving two analyses: one based on 
2016 cross-sectional data; and the other one employing 2007-2017 panel data. Finally, section 
7 describes the conclusions drawn from the present study. 
2. THE MARKET FOR PHARMACEUTICAL PRODUCTS 
This section provides an overview of the main characteristics regarding the market for 
pharmaceutical products. Note that the terms pharmaceutical product and medicine are used 
interchangeably along this paper. The issues addressed, concerning pharmaceutical products, 
are: (i) Definition and classification; (ii) supply and demand; and (iii) international trade. 
2.1. Definition and classification of pharmaceutical products 
The Spanish Ministerio de Sanidad, Consumo y Bienestar Social (2020a) defines 
pharmaceutical products as “every medicinal substance and its associations or combinations 
intended for human or animal use, that feature properties for prevention, diagnosis, 
treatment, relief or cure of diseases, or for affecting body functions or mental state”. 
Medicines may be classified according to various criteria, including: (i) Process of creation 
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(Otero García-Castrillón, 2006); (ii) distribution (OECD, 2019); and (iii) trade purposes 
(World Customs Organization, 2020; European Commission, 2020a), among others.  
Regarding the process of creation, (i) drugs protected by a patent, and (ii) generic drugs exist 
(Otero García-Castrillón, 2006). The former are “medicines created as a result of a long and 
costly R&D process” (Montpart & Martín, 2001). Consequently, their price is substantially 
higher than that of generics. Regarding generics, they are “drugs developed from the 
experience of an innovative medicine, as they contain the same active pharmaceutical 
ingredient, in the same quantity” (Montpart & Martín., 2001).  
Concerning the place where these products are distributed, (i) retail pharmaceuticals, and (ii) 
hospital pharmaceuticals exist (OECD, 2019). The OECD (2019) defines retail 
pharmaceuticals as “provided outside hospital care, such as those dispensed through a 
pharmacy”, while hospital pharmaceuticals “include drugs administered or dispensed during 
an episode of hospital care”.   
As for the classification of medicines based on trade purposes, it draws from that provided 
by the 2017 Harmonized System (HS) Nomenclature, developed by World Customs 
Organization. It is arranged in chapters, being pharmaceutical products covered in Chapter 
30 of the HS 2017 Nomenclature (World Customs Organization, 2020). The HS 2017 
Nomenclature headings of interest to the present paper, which are the ones included in the 
definition of medicines by World Trade Organization (2020a), are presented in Table 1.  
Table 1 
HS 2017 Nomenclature headings and description of pharmaceutical products 
Source: Own compilation based on data from World Customs Organization (2020). 
2.2. Supply and demand of pharmaceutical products 
On the one hand, the pharmaceutical industry is characterized by high R&D investment 
rates, since the competitive advantage of pharmaceutical laboratories lies in innovations. In 
fact, “on average across OECD countries, the industry spent nearly 12% of its gross value 
HS Heading Description 
3002 
Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; 
antisera, other blood fractions and immunological products, whether or not modified or 
obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-
organisms (excluding yeasts) and similar products. 
3003 
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more 
constituents which have been mixed together for therapeutic or prophylactic uses, not put 
up in measured doses or in forms or packings for retail sale. 
3004 
Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or 
unmixed products for therapeutic or prophylactic uses, put up in measured doses (including 
those in the form of transdermal administration systems) or in forms or packings for retail 
sale. 
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added on R&D” (OECD, 2019). Evidence from UNCTAD (2019) shows that 
pharmaceutical companies were the ones exhibiting the highest R&D intensities2 among 
world Top 100 Multinational Enterprises in 2018. 
It is worth of mention that developing a new drug is a costly and risky task, as it takes around 
ten to fifteen years to develop and commercialize a new medicine, while there is little 
certainty about the final result along the process (Priede Bergamini et al., 2009). Thus, many 
of the companies operating in the pharmaceutical sector are large multinationals, while there 
also exist numerous small national biotechnological firms in the sector, which frequently 
license their rights to large companies (Otero García-Castrillón, 2006; ICEX, 2019).  
Furthermore, the pharmaceutical industry has a high market concentration. Evidence 
provided by Christel (2019) suggests that the ten world largest pharmaceutical producers by 
sales covered 51.64% of the market share in the industry3 in 2018. Table 1A in Annex 1 
provides some indicators of the structure of the pharmaceutical sector, for world largest fifty 
pharmaceuticals in 2018. Note that high market concentration in the sector empowers these 
companies for deciding about quantities to be produced and their prices in the market.  
In addition, there is also geographical concentration in the pharmaceutical sector. 
Considering the world largest fifty pharmaceutical manufacturers in 2018, 40% were based 
in Europe, 34% in US and 16% in Japan (Christel, 2019). Likewise, the sector is characterized 
by a high degree of internationalization, probably due to the need to serve large markets so 
as to cover the high costs incurred by pharmaceutical companies (Priede Bergamini et al., 
2009). According to World Trade Organization (2020a), world exports of medicines in 2019 
amounted to $547.69 billion, while imports had a value of $566.33 billion.  
On the other hand, the demand of medicines has increased in recent years, as a consequence 
of the ageing of the population and the prevalence of degenerative chronic illnesses in 
developed countries, among others (ICEX, 2019).  
The demand of medicines in developed countries is considered to have a low elasticity, since 
national governments are the main direct clients (Otero García-Castrillón, 2006). Evidence 
shows that, in OECD countries, government funding and compulsory financing schemes 
were the most important players in the demand of medicines, as they represented 58% of 
total spending on retail pharmaceuticals in 2017 (OECD, 2019). In addition to the co-
 
2 R&D expenditure as a percentage of total revenue. 
3 For the purpose of studying the structure of the pharmaceutical industry, the market is considered to be 
made up of the fifty firms included in Table 1A in Annex 1. 
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financing of medicines for citizens, government adopted measures in this context include 
the reduction of prices set by manufacturers (Otero García-Castrillón, 2006; OECD, 2019). 
The main purpose of the cited public interventions is to grant access to medicines and ensure 
public health. Moreover, Jacobzone (2000) claims that “a higher share of public spending in 
pharmaceutical spending increases pharmaceutical expenditure”.  
Even when no reimbursement exists for consumers, and especially in developed countries, 
buyers are still willing to pay high prices for certain medicines. This means that “the demand 
for many drug products is fairly inelastic up to rather high price levels before income effects 
begin imparting appreciable elasticity” (Scherer, 2000). Furthermore, pharmaceutical 
spending appears to increase linearly with income (Jacobzone, 2000). However, even if price 
intervention by the State exists in developing countries, policy inefficiency causes demand of 
medicines to be elastic, as most pharmaceutical expenditure in these countries comes from 
out-of-pocket payments (Otero García-Castrillón, 2006).  
2.3. International trade in pharmaceutical products  
Medicines are considered as products with a high added value in economic terms, while 
having a large strategic value from the health and industrial perspective. Since they are 
essential for granting public health, and may bring important consequences to the latter, they 
are the most regulated products by states (Antoñanzas et al., 2005).  
2.3.1. World.  
The legal framework governing international trade in medicines is determined by the norms 
included in World Trade Organization’s (WTO) Agreements.  
The General Agreement on Tariffs and Trade 1994 (GATT-1994) establishes the norms aimed at 
reducing or eliminating tariff and non-tariff barriers to trade among Member States, 
prohibiting discrimination. As a result of the Uruguay Round negotiations, twenty-two 
countries4, which together produced 90% of world pharmaceutical production, agreed on 
reciprocal tariff elimination on medicines and substances used for their production, in the 
1994 WTO Pharmaceutical Agreement (Office of the United States Trade Representative, 2020). 
Current participants in this agreement are Canada, EU, Japan, Macao (China), Norway, 
Switzerland and US (World Trade Organization, 2020a).  
Nowadays, medicines are the medical goods with the lowest average Most Favored Nation 
(MFN) tariff applied by WTO members, with an average MFN tariff of 2.1% applied by the 
 
4 Australia, Austria, Canada, Czech Republic, European Communities, Finland, Japan, Norway, Slovak 
Republic, Sweden, Switzerland and US.  
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latter on pharmaceutical products (World Trade Organization 2020a). However, there exists 
inter-country variation in the tariffs applied, being the MFN tariff applied currently by the 
EU on medicines 0% (World Trade Organization, 2020a).  
Nevertheless, Technical Barriers to Trade and Sanitary and Phytosanitary (SPS) Measures are applied 
on trade in medicines. With the purpose of avoiding discrimination and the existence of 
unnecessary barriers to trade posed by these measures, the Agreement on Technical Barriers to 
Trade and the Agreement on SPS Measures exist. These complementary agreements only allow 
the implementation of protectionist measures if they are aimed at protecting public health 
(World Trade Organization, 2011, 2020b). Moreover, Intellectual Property Rights may also 
affect trade in medicines. They are regulated in the Agreement of Trade-Related Aspects of 
Intellectual Property Rights (TRIPS), which pursues the liberalization of trade in products that 
are protected by intellectual rights, maintaining an equilibrium between the protection of the 
cited rights and that of public interests, such as health (Otero García-Castrillón, 2006; World 
Trade Organization, 2020c).  
2.3.2. European Union 
Regarding extra-EU trade, the European Commission (EC) and the European Medicines 
Agency (EMA) cooperate with partner organizations from all around the world, by means 
of bilateral and multilateral relations. 
As for bilateral relations, they generally take place through bilateral regulatory dialogue, which 
exists with the US, China and India (European Commission, 20202b). Confidentiality 
Arrangements and Mutual Recognition Arrangements (MRA) are also of great importance 
in this sense. The former enable the sharing of confidential information between regulatory 
authorities, and are in place with Australia, Canada, Japan, Switzerland and US (European 
Commission, 2020b). On the question of MRAs, they pursue promoting market access of 
medicines and boosting “international harmonization of compliance standards”, without 
giving up public health (European Medicines Agency, 2020). Currently, MRAs exist with 
Australia, Canada, Israel, Japan, New Zealand, Switzerland and US (European Commission, 
2020b). Regarding multilateral relations, the EMA cooperates with authorities from different 
countries in multilateral coalitions and initiatives, such as the International Coalition of 
Medicines Regulatory Authorities, mainly aimed at the convergence of global standards and 
at the sharing of regulatory and scientific information (European Commission, 2020b).  
Concerning intra-EU trade, it takes place in the context of the Single Market, where the free 
movement of goods is granted. Nevertheless, technical barriers are still an important issue 
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regarding intra-EU trade in products such as medicines, which have a direct impact on 
consumer safety (Jordán Galduf & Tamarit Escalona, 2013). Moreover, because of the 
application of the subsidiarity principle5, the pharmaceutical policy of EU Member States is 
fragmented, when it comes to price regulation particularly (Costa-Font & Kanavos, 2004).  
The simultaneous existence of a Single Market and inter-country price differences in the EU 
leads to arbitrage practices known as parallel trade. The latter consists in buying medicines in 
one EU Member State where price is low and reselling them in another EU country, where 
prices are higher and the commercialization of those drugs is also authorized (Costa-Font & 
Kanavos, 2004). Parallel trade in medicines involves trading through channels other than those 
established by the manufacturer and regardless of her will and, in certain countries including 
Spain, it is enough with getting an authorization for the commercialization of the product by 
the parallel trader6 (González-Baizán González-Lamuño, 2018). The European Commission 
(2018) claims that parallel trade in medicines is a legitimate act inside the Single Market, while 
exceptionally allowing for restrictions when justified by the protection of public health. 
3. THE MARKET FOR PERSONAL PROTECTIVE EQUIPMENT 
This section deals with describing the main features present in the market for personal 
protective equipment (PPE). It is composed of three parts, regarding PPE: (i) Definition and 
classification; (ii) supply and demand; and (iii) international trade. 
3.1. Definition and classification of personal protective equipment 
Given the health oriented focus of the present paper, a suitable definition of PPE is that 
formulated by the World Health Organization (2020a), which defines PPE as “garments 
placed to protect the health care workers or any other persons to get infected”. The 
classifications of PPE presented below are those provided by (i) World Trade Organization 
(2020a); and (ii) European Commission (EUR-Lex, 2020b).  
World Trade Organization (2020a) considers being PPE the following: (i) Hand soap; (ii) 
washing and cleaning preparations; (iii) hand sanitizer; (iv) face masks; and (v) protective 
spectacles and visors. This classification of PPE is employed in the sections that follow.  
The EC (EUR-Lex, 2020b) regards PPE to be composed of the following: (i) Protective 
spectacles and visors; (ii) face shields; (iii) mouth-nose protection equipment; (iv) protective 
garments; and (v) gloves. 
 
5 It is aimed at ensuring that “decisions are taken as closely as possible to the citizen” (EUR-Lex, 2020a). 
6 If no reconditioning, packaging and/or relabeling is to be performed by the trader. 
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3.2. Supply and demand of personal protective equipment 
The PPE market has a high degree of internationalization, with trade in PPE7 having an 
average value of $135 billion in the period 2017-2019 (World Trade Organization, 2020a). 
Given the low profit margins on most of these products, they are mainly produced in Asia, 
where labor costs are significantly lower than in western economies (Deutsche Welle, 2020). 
Thus, most countries rely on China for imports of PPE (Peterson Institute for International 
Economics, 2020a). Regarding the EU, production of PPE is concentrated in a small number 
of countries including Czech Republic, France, Germany and Poland (EUR-Lex, 2020b).  
According to World Trade Organization (2020a), 17.2% of the exports of these products 
came from China in the period 2017-2019, 12.7% of them were produced in Germany, and 
the US was the country of origin of 10.2% of them. If the PPE definition provided by the 
EC is regarded, 43% of total world imports of these products in 2018 came from China, 
while being China the of origin of 50% of imports of PPE by the EU in the same year 
(Peterson Institute for International Economics, 2020a).  
Regarding the demand of PPE, it is not limited to the health care sector. However, given the 
health orientation of this paper, the focus will be placed in the latter. In this sense, the main 
purpose of PPE is to protect health care workers, as well as citizens in face of a pandemic 
(World Health Organization, 2020b).  
PPE represented 13% of world medical product imports in 2019, and the US and Germany 
were the largest importers of PPE8 in that year, as their imports accounted together for more 
than 22% of total world imports of the cited products (World Trade Organization, 2020a).  
3.3. International trade in personal protective equipment 
Although not being as highly regulated as medicines, due to their effect on citizens’ health, 
there exist strong regulations on PPE. Most of the regulation is materialized in certificates of 
compliance with the safety standards established by countries on the cited products.  
Moreover, tariff barriers pose significant obstacles to international trade in PPE (World 
Trade Organization, 2020a). The average MFN tariff applied by WTO member countries to 
PPE relevant for Covid-19 is 11.5%, more than five times greater than that applied on 
medicines by the same countries (World Trade Organization, 2020a). Furthermore, if 
analyzing separately PPE products, hand soap has an average MFN tariff of 17% regarding 
WTO members, whereas the average MFN tariff on hand sanitizers is of 5% and that on 
 
7 As defined by World Trade Organization (2020a).  
8 As defined by World Trade Organization (2020a). 
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face masks of 9.1% (World Trade Organization, 2020a). Nevertheless, the application of 
tariffs varies among the countries considered. According to World Trade Organization 
(2020a), the latest average MFN tariff applied on Covid-19 PPE products by the EU is 3.9%.  
4. COVID-19: CURRENT SITUATION OF TRADE IN MEDICAL PRODUCTS 
The current global health emergency situation caused by Covid-19 has significantly affected 
trade in medical goods, especially that in PPE. It has led to increases in the stocking levels 
of PPE by countries, so as to keep medical workers safe and prevent the propagation of the 
virus. Consequently, the demand of these products has increased globally, and so has import 
demand, as many countries are highly dependent on PPE imports.  
Nevertheless, many international orders of PPE in recent months have not arrived at the 
buying country in the previously agreed conditions. In fact, in some cases products arrive at 
a later date than that initially agreed upon, in other instances a lower amount of the goods is 
received, while it may even be the case that no product reaches the importing country. There 
are two main reasons explaining these happenings: (i) Intercepts of shipments bought by 
some countries, by other countries, and (ii) trade restrictive policy measures implemented by 
states. A more detailed account of these issues follows. 
4.1. Intercepts of shipments 
Intercepts of shipments ordered by other countries consist in diverting shipments of PPE 
intended for other countries by outbidding the original importer. Although this behavior is 
not allowed under international trading rules, it has become a reality in the context of the 
Covid-19 pandemic. For instance, the US has been blamed by several countries, including 
Brazil, Canada, France, Germany and Paraguay, for having intercepted their shipments of 
PPE ordered to China. According to authorities in these countries, US buyers went to 
Chinese airports where shipments were about to be sent to their destination countries, they 
paid upfront three to four times the price paid by original buyers, and diverted shipments to 
the US (El País, 2020; Financial Times, 2020).  
4.2. Trade policy measures 
Many countries have implemented export restrictions on medical products, which are 
justified on public health reasons. Among these countries, the EU is found. At the start of 
Covid-19 pandemic, the EC published a regulation requiring that all exports of PPE to 
countries outside the EU were subject to an export authorization by Member States (EUR-
Lex, 2020b). Nevertheless, the EC subsequently amended this Regulation restricting the cited 
export authorization to protective masks, spectacles and garments (EUR-Lex, 2020c). 
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In addition to EU Member States, four OECD Member Countries have recently adopted 
trade restrictive measures. In this sense, Switzerland has established exports of PPE and vital 
medical goods subject to export authorization, while South Korea, Australia and the UK 
have implemented export bans on face masks, non-commercial exports of PPE and certain 
medicines, respectively (World Trade Organization, 2020d). Concerning extra-OECD 
territories, twenty-six9 of them have also implemented temporary export restrictions and/or 
prohibitions on medical goods recently (World Trade Organization, 2020d).  
However, not every country agrees on the implementation of protectionist measures for 
fighting Covid-19. In this sense, Australia, Brunei Darussalam, Canada, Chile, the Republic 
of the Union of Myanmar, New Zealand and Singapore have recently committed to remove 
existing trade barriers on medical products (World Trade Organization, 2020d). 
Furthermore, the US has excluded temporarily certain Chinese exports from additional tariffs 
(World Trade Organization, 2020d). In the same vein, the EC appealed the EU Member 
Countries to include measures at national level that would guarantee the availability of PPE 
across the EU where needed, as Member States were requested to minimize border-crossing 
procedures to what it is rigorously necessary (European Commission, 2020c).  
Besides, export restrictions on PPE by China, being many countries dependent on the latter, 
have not taken place. In fact, trade measures adopted by China in this context include 
decreasing temporarily import tariffs on medical equipment, and exempting certain US 
imports from additional tariffs (World Trade Organization, 2020d). However, China 
eventually limited exports of medical goods to those products that have obtained a license 
for commercialization in the Chinese market, as a consequence of existing deviations 
between actual quality and that claimed by the exporting company in some international 
purchases, such as the acquisition of test kits by the Spanish Government (Ministerio de 
Sanidad, Consumo y Bienestar Social, 2020b).  
Moreover, according to World Trade Organization (2020f), WTO members have liberalized 
trade in more than 84% of medical goods inside their Regional Trade Agreements by 2020. 
4.3. Consequences 
Among the most affected parties by these measures aimed at fighting Covid-19, developing 
countries are found. A relevant amount of exports of PPE by developed countries are 
 
9 Albania; Algeria; Argentina; Azerbaijan; Bangladesh; Brazil; Colombia; Costa Rica; Ecuador; Georgia; India; 
Indonesia; Kyrgyz Republic; Malaysia; Moldova; Morocco; Pakistan; Paraguay; Peru; Russian Federation; 
Serbia; South Africa; Separate Customs Territory of Taiwan, Penghu, Kinmen and Matsu; Sri-Lanka; Thailand 
& Ukraine. 
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directed to these nations, which are often reliant on them, while many developing countries 
lack the domestic industry necessary for self-supply of the products in matter. Thus, 
international trade is an essential tool for alleviating the effects of Covid-19 in these countries 
(Peterson Institute for International Economics, 2020c). For instance, countries located in 
Eastern Europe, north of Africa and Sub-Saharan Africa highly depend on EU exports of 
certain PPE products, as they make up more than 50% of their total imports of these goods 
in some cases (Peterson Institute for International Economics, 2020b).  
However, the cited measures have also led to a shortage of PPE in developed countries, 
causing increases in prices of PPE and encouraging self-supply of these goods by states. 
Moreover, export bans may halt cross-border supply chains of medical goods that are vital 
in the context of the Covid-19 pandemic. What is more, they may disrupt exports of inputs 
to third countries that manufacture the medical goods subsequently imported by the country 
imposing the ban. Besides, these measures may induce the trading partners of the countries 
imposing the export ban to adopt export restrictions too, as a response to their beggar-thy-
neighbor policy. Given that EU imports of the products initially subject to its own export 
restrictions amounted to $17.6 billion in 2019 (Peterson Institute for International 
Economics, 2020b), these measures might have a significant impact on public health.  
According to Peterson Institute for International Economics (2020c), trade measures to 
sustain health care systems and save lives should be adopted. These include (i) decreasing 
tariffs in medicines and other medical goods, (ii) facilitating cross-border movement of health 
products, (iii) making available technical standards by countries, and (iv) ensuring that 
intellectual property regulation does not obstruct access to medical goods.   
5. TRADE IN MEDICAL PRODUCTS BETWEEN SPAIN AND THE REST OF 
THE WORLD 
Firstly, the evolution of Spanish trade flows of medical products with the rest of the world 
for the period 1995-2018 is presented in this section, followed by a description of the main 
Spanish trading partners for these products in 2019.  
5.1. Spanish trade in medical products in the period 1995-2018 
The evolution of Spanish imports and exports of medical products10 with the rest of the 
world, together with the trade balance for these goods, for the period 1995-2018, is displayed 
in Figure 1.  
 
10 Medicines and PPE, as defined by World Trade Organization (2020a). 
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Figure 1. Spanish imports and exports (million 2010 US $) of medical products for the period 1995-2018. 
Source: Own compilation based on data from DataComex (2020). 
As evidenced by Figure 1, Spanish imports and exports of medical products have followed a 
similar trend throughout the period considered. From 1995 to 2002, both trade flows 
experienced a rather constant and slow growth. Beginning in year 2002, imports and exports 
increased their growth rates considerably, coinciding with the entry into circulation of the 
Euro11. Presumably, progress in technical harmonization regarding intra-EU trade in 
medicines has also contributed to the cited acceleration in growth rates, being worth of 
mention a Directive passed by the European Parliament and the Council on the 
establishment of a Community code for human medicines in 2001 (EUR-Lex, 2020d).  
Since 2008, year to which the beginning of the global financial crisis is attributed, the values 
of Spanish imports and exports of medical goods have undergone slight fluctuations but 
have remained around their 2008 levels. This behavior in world trade flows of medical 
products, which is noteworthy given that trade in other goods fell significantly as a 
consequence of the crisis (Eurostat, 2020), is probably due to their essential nature regarding 
citizen’s health. With respect to the Spanish trade balance for medical goods, Figure 1 shows 
that it has been negative for Spain for the duration of the whole period.  
5.2. Main Spanish trading partners for medical products in 2019 
The main five trading partners of Spain regarding imports and exports of medicines12 in 2019 
are presented in Figure 2. Interestingly, four of the five most important Spanish trading 
partners for medicines coincide for imports and exports, yet their order of relevance differs 
 
11 Spain and twelve of the countries in the sample had the Euro as their national currency in 2008.  
12 As defined by World Trade Organization (2020a). 
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between both trade flows. This fact evidences the importance of intra-industry trade in the 
pharmaceutical sector.  
Intra-industry trade is defined as bilateral trade in different varieties of goods belonging to 
the same industry, and it generally takes place between countries which have similar factor 
endowments. This kind of trade is explained by imperfect competition models, which are 
based on economies of scale, leading to the concentration of production on a small number 
of firms (Krugman, 1980; Krugman et al., 2018).  
Figure 2. Main trading partners for trade in pharmaceutical products for Spain in 2019.                                       
Source: Own compilation based on data from DataComex (2020). 
Furthermore, three of the five most relevant countries regarding Spanish medicine trade 
belong to the EU, whereas the most important trading partner of Spain in both cases is an 
extra-EU country: US in the case of imports and Switzerland in the case of exports. These 
findings go in line with data about the EU, since US and Switzerland were the most important 
trading partners of the EU considering trade in medicines in 2019 (Eurostat, 2020). 
Moreover, with respect to Member States, Germany, the Netherlands and France were 
among the largest exporters of medicines in 2019 (Eurostat, 2020), which may explain why 
they are part of the five most important trading partners for Spain in 2019 regarding imports 
of the products in matter. Likewise, Germany was one of the most relevant destinations for 
Spanish exports of medicines in 2019, while evidence from Eurostat (2020) shows that it was 
the third largest medicine importer among EU Member States in the same year.  
Spain’s trading partners for trade in PPE13 are displayed in Figure 3. One could argue that 
some degree of intra-industry trade is also present in the industry of PPE, since three of the 
five most relevant trading partners for Spain coincide both for imports and exports. 
Nevertheless, with respect to at least some PPE products, such as face masks, trade is mainly 
justified by differences in factor endowments. As for imports, Germany and France are the 
 
13 As defined by World Tarde Organization (2020a). 
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two most important Spanish trading partners, while being two of the countries at which EU 
production of these goods is concentrated (EUR-Lex, 2020b). China is the third country 
with the highest share in Spanish imports of PPE, which is sensible given that it was the 
world largest exporter of these products in 2019 (World Trade Organization, 2020a). 
Concerning Spanish exports of PPE, the top five trading partners for Spain are EU 
members14. Besides, the two main destination countries for Spanish exports of PPE are 
Portugal and France, which are both neighboring countries to Spain.  
Figure 3. Main trading partners for trade in personal protective equipment for Spain in 2019.                      
Source: Own compilation based on data from DataComex (2020). 
6. EMPIRICAL ANALYSIS OF SPANISH IMPORTS OF MEDICAL PRODUCTS 
FROM OECD COUNTRIES AND CHINA 
This section presents an econometric analysis of Spanish imports of medical products from 
OECD countries and China. The focus has been narrowed to this group of countries since 
92.84% of medicine imports and 95.11% of PPE imports by Spain in 2019 had their origin 
in OECD countries and China (DataComex, 2020).  
The first part of the section provides the theoretical background of the Gravity Model of 
world trade, as the econometric models presented in the following subsections draw from it. 
The second and third parts are concerned with modelling 2016 cross-sectional data and 2007-
2017 panel data about Spanish imports of medical products from OECD countries and 
China, respectively.  
An econometric analysis has also been performed for Spanish exports of medical products 
to OECD countries and China. Regarding 2016 cross-sectional data, variations in Spanish 
exports of both medicines and PPE seem to be positive if, other things equal, the GDP or 
the share of pharmaceutical spending on health spending in Spain’s trading partner rise by 
 
14 UK left the EU on 31/01/2020. 
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1%, while a 1% ceteris paribus increase in the distance between Spain and the importing 
country causes a negative variation of exports regarding both medical products considered. 
Moreover, EU membership by the importing country appears to affect only Spanish exports 
of medicines, positively. For 2007-2017 panel data, exports of both medical goods appear to 
increase when the GDP of the importing country increases by 1%, ceteris paribus. EU 
membership by Spain’s trading partner has been found as having no effect on Spanish 
exports of neither medical good, while a 1% increase in the number of researchers in the 
importing country appears to affect only exports of PPE, positively.  
Since these conclusions do not appear to be consistent with the industry characteristics and 
trade regulation concerning the products considered, it has been decided not to include the 
analysis of Spanish exports of medical goods in the present paper, and to focus on imports. 
6.1. Gravity model 
The Gravity Model of world trade was named after Newton’s law of gravity, since it is based 
on the idea that “trade between any two countries is, other things equal, proportional to the 
product of their GDPs and diminishes with distance” (Krugman et al., 2018). Tinbergen 
(1962) was the first person employing this model to explain international trade flows and, 
nowadays, it is one of the most popular econometric models in international trade.  
Equation (1) is used for estimating trade between two countries. Where, K is the regression 
constant to be fitted to real data, Tij is the value of trade between country i and country j, Yi 
is country i’s GDP, Yj is country j’s GDP, and Dij is the distance between country i and 
country j. Furthermore, a, b and c are indexes introduced so as to get a better fit of real data. 
𝑇𝑖𝑗 = 𝐾
𝑌𝑖
𝑎∗𝑌𝑗
𝑏
𝐷𝑖𝑗
𝑐      (1) 
According to Equation (1), the determinants of the value of trade between two countries, i 
and j, are the GDPs of both countries and the distance between country i and country j. In 
fact, other things equal, a higher value of the GDP of either country, which is a proxy of the 
size of their economies, will lead to a higher value of trade. The reason behind is that 
economies with larger GDPs (i) tend to produce more products and, consequently, draw in 
more foreign spending, and (ii) they often have larger incomes, which may lead to spending 
more in consumption and, thus, also in imports. However, trade costs negatively affect the 
value of trade between country i and country j. Distance is the most commonly used proxy 
for trade costs, since it usually involves larger transport costs.  
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The gravity model is also useful for analyzing anomalies in trade. Some of the factors that 
may explain why the value of trade between two countries is far from that predicted by the 
gravity model are (i) cultural similarities such as language, (ii) adjacency, (iii) colonial links, 
(iv) trade agreements, (v) geography, (vi) bilateral exchange rates between currencies, and, in 
case trade flows of a particular industry are being analyzed, (vii) specific characteristics of the 
industry, among others. Cultural similarities, adjacency, colonial links and trade agreements 
are expected to positively affect trade flows between two countries.   
6.2. Cross-sectional analysis for 2016 
Based on the Gravity Model, a model for Spanish imports of medical goods for year 2016 is 
constructed in this section. Although data about the aforementioned imports is available for 
years after 2016, the existing lack of data regarding some of the relevant variables for the 
study concerning certain countries for subsequent years, would lead to weaker estimations. 
Thus, Spanish imports of medical products from OECD countries and China in 2016 are 
analyzed.   
The analysis is performed with the econometrics package Gretl. The aim is to find the OLS 
estimators of the constant and the parameters for the regressors determining the considered 
trade flows. For this purpose, a cross-sectional database consisting of thirty-six cross-sections 
(countries) and six variables has been constructed. The countries included are the thirty-five 
OECD member countries15 (other than Spain) and China, while the variables incorporated 
are described in the next section. 
6.2.1. Variables 
Data about Spanish imports of medical products has been retrieved from DataComex, the 
database containing Spanish foreign trade statistics. Imports in the database are measured in 
current US$. Thus, they have been transformed into constant 2010 US$ by using the Spanish 
GDP deflator obtained from the World Development Indicators database provided by World 
Bank. Total imports of medical goods are disaggregated into imports of (i) medicines16 and 
(ii) PPE17, as defined by World Trade Organization (2020a). Imports are included as “IM” in 
 
15 Australia, Austria, Belgium, Canada, Chile, Czech Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Luxembourg, Mexico, 
Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Sweden, Switzerland, 
Turkey, United Kingdom and United States. Although Colombia joined the OECD on 28/04/2020, it is not 
included in the analysis.  
16 HS 2017 Headings 3002, 3003 and 3004 (World Trade Organization, 2020a). 
17 Hand soap, washing and cleaning preparations, hand sanitizer, face masks, and protective spectacles and 
visors (World Trade Organization, 2020a).   
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the following models. Furthermore, given the differences in the nature of medicines 
belonging to different HS headings, a separate analysis for each group is also performed.  
The size of a country’s economy is proxied by the GDP of the country. Data about GDP 
expressed in constant 2010 US$ has been retrieved from the World Bank database for the 
thirty-six member countries of OECD, including Spain, and China. “GDPi” will denote the 
Spanish GDP, whereas “GDPj” stands for that of exporting countries.  
Distance, denoted by “Dij”, is employed as a proxy for trade costs, it is measured in 
kilometers and it has been obtained from the GeoDist database by CEPII. Distances are 
computed “following the great circle formula, which uses latitudes and longitudes of the 
most important cities/agglomerations (in terms of population)” (Mayer & Zignago, 2011).  
European Union (2020) data have been employed to construct a dummy variable indicating 
membership to the EU by Spain’s trading partners. This variable, denoted by “EU”, takes 
value 1 when the exporting country is an EU Member State, and 0 otherwise. 
Given the importance of R&D investments on the pharmaceutical industry, data about the 
number of researchers in R&D per million people for each country has been retrieved from 
the World Development Indicators database provided by the World Bank. The purpose of 
including this explanatory variable is to proxy R&D activity in the countries considered. This 
regressor will be denoted by “RD”, and it will be referred to as “number of researchers”. 
Likewise, data about high-technology exports as a share (%) of total manufacture exports of 
countries has been obtained from the World Development Indicators database by World 
Bank. High-technology exports refer to “products with high R&D intensity” (World Bank, 
2020). According to the Heckscher-Ohlin theorem, the more relatively abundant a factor is 
in one country, the more concentrated are its exports in sectors with a higher relative intensity 
in that factor (Krugman et al., 2018). Thus, this regressor has been introduced aimed at 
proxying the relative abundance of knowledge in each country. The variable will be included 
as “HTEX” in the models, and it will be referred to as “share of high-technology exports”. 
6.2.2. Variable and model transformations 
Variables are checked for normality prior to modelling imports since, if data about the 
variables does not follow a normal distribution, usually normality of the error does neither 
hold. Among the implications of lacking normality in data, the possible loss of validity of 
hypothesis testing is found (Universidad Complutense de Madrid, 2013). The Jarque-Bera 
(JB) test is employed for this purpose, where the null hypothesis claims normality of data. 
For a 5% significance level, variables reporting a p-value smaller than 0.05 are not considered 
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normally distributed. According to the JB Test, imports of all the medical goods regarded, 
the GDPs of Spain’s trading partners and the distance between Spain the exporting country 
do not follow a normal distribution. Consequently, as they only take strictly positive values, 
they are included in logarithmic form in the models. The p-values resulting from the JB test 
are provided in Table 2A in Annex 2 to the present paper. 
Heteroskedasticity, which refers to the lack of a constant variance of the error of the General 
Linear Model, also leads to inefficient OLS estimators. With the purpose of basing the 
present analysis on homoscedastic models, all the models are tested for heteroskedasticity by 
the means of White’s Test. The null hypothesis in this test claims homoscedasticity. 
Therefore, for a 5% significance level, those models reporting a p-value smaller than 0.05 are 
considered heteroskedastic and, thus, have been corrected for heteroskedasticity. The p-
values resulting from White’s Test are found in Table 3A in Annex 2 to the present paper. 
6.2.3. Analysis of Spanish imports of medical products in 2016 
Table 2 
Value of 2016 Spanish medical product imports by groups  
Goods 
Value  (constant  
2010 US $) 
Share on total 
imports 
Total Medicines             12,402,516,477  89.56% 
3002 - Blood, vaccines and similar products.               2,644,462,127  21.32% 
3003 - Medicaments not put up in doses or packagings for sale*                 233,952,673  1.89% 
3004 - Medicaments put up in doses or packagings for sale*               9,524,101,677  76.79% 
Personal Potective Equipment              1,445,796,976  10.44% 
Total Medical Products             13,848,313,453    
* 
Excluding goods of heading 3002.   
Source: Own compilation based on data from DataComex (2020).  
From data in Table 2, it is apparent that the value of Spanish medicine imports as a share of 
the total Spanish medical product imports considered is more than eight times that of 
imports of PPE in 2016. Moreover, in the same year, more than 75% of Spanish medicine 
imports correspond to medicines under HS heading 3004.  
Different models are introduced for “Total medicines”, “HS 3002 medicines”, “HS 3003 
medicines”, “HS 3004 medicines” and “PPE” imports by Spain. 
𝑙_𝐼𝑀𝑖𝑗 =  𝛼 + 𝛽1𝐺𝐷𝑃𝑖 + 𝛽2𝑙_𝐺𝐷𝑃𝑗 + 𝛽3𝑙_𝐷𝑖𝑗 + 𝑢𝑖𝑗          (Model 1) 
The first model (Model 1) to be analyzed is the basic Gravity Model. β1 stands for the mean 
percentage (expressed as per-unit) ceteris paribus effect of increasing Spanish GDP by one 
US$ on the predicted value of Spanish imports of the product in matter. β2 is the mean ceteris 
paribus percentage variation in the predicted value of Spanish imports of the considered 
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product when the GDP of Spain’s trading partner is increased by 1%. β3 represents the mean 
percentage change in the predicted value of Spanish imports of the product analyzed, when 
distance between Spain and the exporting country increases by 1%, other things equal.  
Based on the theoretical background of the Gravity Model, coefficients β1 and β2 are 
expected to be positive in every case. In fact, the larger the size of the economy of the 
countries participating in trade, the larger the value of trade between them is expected to be. 
By contrast, β3 is anticipated to be negative, since the greater the distance between two 
countries, the larger the trade costs are foreseen to be and, thus, the smaller the trade flows 
between them. The coefficients and their respective p-values for Model 1, regarding Spanish 
imports of medical goods, are presented in Table 3 below. 
Concerning Model 1 in Table 3, the sign of the coefficients for GDPj and Dij is the expected 
one in every case. β2 and β3 are significant at a 1% significance level for all the dependent 
variables considered, except for the β2 related to imports of HS 3003 medicines, which is only 
significant at a 5% significance level. In contrast, the coefficient for Spanish GDP does not 
have the expected sign neither for total medicine imports nor for HS heading 3002 and 3004 
imports but, given that it is not possible to state at a 10% significance level that β1 is different 
from zero for none of the dependent variables, it will not be taken into account. 
Furthermore, including the variable GDPi in the model causes the data matrix to be close to 
singularity. Thus, GDPi has been excluded from Model 2. 
Table 3 
Estimations for Model 1 and Model 2 with 2016 cross-sectional data  
  Model 1 Model 2 
 Medicines 
PPE 
Medicines PPE 
Ind. v./ 
Dep. v. Total
HC
 3002 3003 3004 Total
HC
 3002 3003 3004
HC
 
 
Constant 4.96E+15 7.43E+16 -9.63E+14 5.01E+15 -5.51E+14 -2.28E+00 -20.8841** 1.37E+01 -1.88E-01 -5.29E+00 
p-value 0.2044 0.4023 0.5514 0.1311 0.7932 0.641 0.0364 0.1798 0.9781 0.213 
GDPi -3392.63 -50832.2 658.408 -3429.95 377.179       
p-value 0.2044 0.4023 0.5514 0.1311 0.7932       
l_GDPj 1.3001*** 1.8063*** 0.8443** 1.5328*** 1.2918*** 1.3811*** 1.8158*** 0.8359** 1.4644*** 1.2906*** 
p-value 2.73E-08 1.04E-05 0.0347 2.77E-07 1.13E-09 8.11E-10 8.15E-06 0.0336 3.87E-07 6.44E-10 
l_Dij -1.1490*** -1.9491*** -2.9223*** -2.7072*** -1.7048*** -2.2279*** -1.7407** -2.9526*** -2.8402*** -1.7341*** 
p-value 1.36E-08 0.0087 0.0005 4.11E-06 5.97E-06 5.74E-06 0.0113 0.0004 2.76E-06 1.06E-06 
Adj. R2 0.6769 0.4529 0.3672 0.6212 0.7081 0.7035 0.4577 0.3839 0.6259 0.7163 
HCHeteroskedasticity corrected; ***p-value<0.01, **p-value <0.05, *p-value<0.1 
Source: Own compilation based on data from Gretl. 
𝑙_𝐼𝑀𝑖𝑗 =  𝛼 + 𝛽1𝑙_𝐺𝐷𝑃𝑗 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝑢𝑖𝑗          (Model 2) 
Regarding Model 2, β1 is expected to be positive and β2 to be negative because of the 
aforementioned reasons. The coefficients and their respective p-values for Model 2, 
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regarding Spanish imports of medical goods, are displayed in Table 3 above. The conclusions 
drawn for the coefficients of GDPj and Dij in Model 2 are identical to those described for 
Model 1, except for the β2 corresponding to imports of HS 3002 medicines, which is now 
significant at a 5% significance level.  
𝑙_𝐼𝑀𝑖𝑗 =  𝛼 + 𝛽1𝑙_𝐺𝐷𝑃𝑗 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝛽3𝐸𝑈𝑗 + 𝑢𝑖𝑗    (Model 3) 
The variable named EU is introduced in Model 3, aimed at measuring the effect of barriers 
to trade on Spanish imports of medical products. As previously mentioned, the latest MFN 
tariff applied by the EU on medicines and PPE is 0% and 3.9%, respectively (World Trade 
Organization, 2020a). Moreover, non-tariff barriers, such as technical barriers, affect world 
trade in medical goods. The existence of barriers to trade is expected to lead to higher imports 
from EU Member Countries than from the rest of the world, especially in the case of PPE, 
as higher tariffs to imports from extra-EU countries are applied. β3 denotes the mean ceteris 
paribus percentage change (expressed as per-unit) in the predicted value of Spanish imports 
of the goods in matter caused by EU membership by the exporting country, and it is expected 
to be positive. The coefficients obtained and the p-values associated to them for Model 3, 
regarding Spanish imports of medical goods, are presented in Table 4.  
Table 4 
Estimations for Model 3 and Model 4 with 2016 cross-sectional data 
  Model 3 Model 4 
 Medicines 
PPE
HC 
Medicines 
PPE Ind. v./ 
Dep. v. Total
HC 3002 3003 3004 Total 3002 3003 3004 
Constant -6.95E+00 -32.6064** -1.41E+01 -9.44E+00 -7.9554* -11.3045* -39.3261*** -27.1829** -1.03E+01 -19.3024*** 
p-value 0.3202 0.0131 0.2554 0.3046 0.0859 0.0756 0.0055 0.0486 0.2369 0.0006 
l_GDPj 1.4135*** 1.9800*** 1.3391*** 1.5986*** 1.2138*** 1.5430*** 2.1565*** 1.5881*** 1.6974*** 1.5853*** 
p-value 2.48E-08 4.08E-06 0.0009 6.25E-07 1.56E-11 1.11E-09 2.12E-06 0.0003 8.97E-08 6.98E-12 
l_Dij -1.8351*** -0.9798 -1.4882* -2.1879*** -1.2282*** -1.9724*** -1.1040 -0.6907 -2.7343*** -1.0921*** 
p-value 7.00E-04 2.44E-01 0.0616 1.10E-03 2.00E-04 4.00E-04 2.79E-01 0.4224 4.00E-04 8.80E-03 
EUj 1.1987* 2.179 4.4569*** 0.7214 1.3205** 1.2118 3.211* 6.0792*** 0.8032 2.7333*** 
p-value 0.0965 0.1564 0.0038 0.5208 0.025 0.1267 0.0557 0.0009 0.459 0.0002 
RDj       0.0005*** 0.0005* -0.0002 0.0006*** -0.0002* 
p-value           0.0023 0.088 0.405 0.0053 0.099 
Adj. R2 0.6683 0.4758 0.5565 0.5980 0.8082 0.8022 0.5900 0.5799 0.7368 0.8419 
HCHeteroskedasticity corrected; ***p-value<0.01, **p-value <0.05, *p-value<0.1 
Source: Own compilation based on data from Gretl. 
Adding the regressor EU to Model 2 leads to having a positive and significant (1% 
significance level) coefficient regarding GDPj for every dependent variable considered. 
Moreover, the Dij coefficient for dependent variable “HS 3002 imports” loses statistical 
significance and that for “HS 3003 imports” is now significant only at a 10% significance 
level. The coefficient for the regressor EU is positive as expected, while it is only significant 
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for total imports of medicines, and for imports of HS 3003 medicines and PPE, at a 10%, 
1% and 5% significance levels, respectively. It is plausible to associate this result with the 
presence of tariff barriers to trade on PPE. As for medicine imports, this may be due to the 
existence of more developed technical harmonization inside the EU for these products, as 
compared to those with extra-EU countries. 
𝑙_𝐼𝑀𝑖𝑗 =  𝛼 +  𝛽1𝑙_𝐺𝐷𝑃𝑗 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝛽3𝐸𝑈𝑗 + 𝛽4𝑅𝐷𝑗 + 𝑢𝑖𝑗          (Model 4) 
Model 4 adds the variable RD, so as to proxy the R&D activity of the countries considered. 
Changes in this variable are expected to be positively correlated with the value of Spanish 
imports of medicines, given the importance of R&D on the manufacturing of these goods. 
In contrast, it is predicted to have no effect or to be negatively correlated with imports of 
PPE, as their production, generally, does not require a high R&D activity. β4 represents the 
mean percentage (expressed as per-unit) ceteris paribus effect on the predicted value of 
Spanish imports of the product in matter, of increasing the number of researchers in the 
exporting country in one person. Thus, β4 is expected to be positive for medicine imports 
and negative or not statistically significant for PPE imports. The coefficients and their 
corresponding p-values, regarding Spanish imports of medical goods, are summarized in 
Table 4 above.  
The conclusions drawn in Model 3 for the coefficients of the regressor GDPj still hold in 
Model 4. Regarding Dij, all the coefficients have the expected negative sign, but that 
corresponding to HS 3003 medicine imports is no longer statistically significant. The 
coefficient for EU is still positive and significant for imports of HS 3003 medicines and for 
imports of PPE, whereas both coefficients are significant at a 1% significance level in Model 
4. Moreover, β3 is now significant at a 10% significance level for imports of HS 3002 
medicines, while it is not possible to state at a 10% significance level that it is different from 
zero in the case of total medicine imports.  
A one person increase in the exporting country’s number of researchers seems to affect 
positively total medicine imports (1% significance level) and imports of medicines under HS 
headings 3002 (10% significance level) and 3004 (1% significance level). Furthermore, this 
variable appears to be negatively correlated with the expected value of Spanish imports of 
PPE (10% significance level), while it appears sensible to associate it with the low R&D 
activity required, in general, for manufacturing PPE. Nevertheless, the size of β4 is very small 
in every case.  
𝑙_𝐼𝑀𝑖𝑗 =  𝛼 + 𝛽1𝑙_𝐺𝐷𝑃𝑗 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝛽3𝐸𝑈𝑗 + 𝛽4𝑅𝐷𝑗 + 𝛽5𝐻𝑇𝐸𝑋𝑗 + 𝑢𝑖𝑗         (Model 5) 
25 
 
Model 5 adds the variable HTEX to Model 4. This regressor represents the share of high-
technology exports of Spain’s trading partners, and seeks to proxy the relative abundance of 
knowledge in the latter. Since the pharmaceutical sector is classified as a high-technology 
manufacturing industry, increases in the share of high-technology exports by countries are 
expected to lead to a higher value of Spanish imports of medicines. However, they are 
foreseen to have no effect or be negatively correlated with imports of PPE, as the latter are 
considered medium-low and low technology products (OECD Directorate for Science, 
Technology and Industry, 2011). β5 measures the ceteris paribus mean percentage (expressed 
as per-unit) change in the predicted value of Spanish imports of the product in matter, when 
the share of high-technology exports of its trading partner is increased in one unit. Therefore, 
β5 is expected to have a positive sign for imports of medicines and to have a negative sign or 
not be statistically significant for imports of PPE. The results obtained when running Model 
5 in Gretl are displayed in Table 5. 
        Table 5 
        Estimations for Model 5 with 2016 cross-sectional data 
 
 
 
 
 
   
 
 
 
 
 
 
     HCHeteroskedasticity corrected; ***p-value<0.01, **p-value <0.05, *p-value<0.1 
     Source: Own compilation based on data from Gretl. 
Model 4 and Model 5 lead to identical conclusions regarding regressors GDPj, and Dij. For 
regressor EU, the results found in Model 4 still hold, except in the case of HS 3002 medicines, 
which is now significant at a 5% significance level. Moreover, Spanish imports of PPE still 
seem to be negatively correlated with the number of researchers in the exporting country at 
a 10% significance level. This also holds for imports of HS 3003 medicines, which appears 
counterintuitive. Furthermore, β4 is still positive for total medicine imports and imports of 
HS 3004 products, but only at a 5% significance level, while that for HS 3002 imports has 
  Model 5 
 Medicines 
PPE Ind. v./ 
Dep. v. 
Total  3002 3003 3004 
Constant -1.01E+01 -37.1206*** -2.02E+01 -9.92E+00 -19.0145*** 
p-value 0.1063 0.007 0.1014 0.2672 0.0009 
l_GDPj 1.5132*** 2.1027*** 1.4300*** 1.6879*** 1.5779*** 
p-value 1.98E-09 2.41E-06 0.0003 2.01E-07 2.27E-11 
l_Dij -2.0984*** -1.4020 -1.1965 -2.7745*** -1.1234*** 
p-value 2.00E-04 1.66E-01 0.1378 5.00E-04 9.40E-03 
EUj 1.2732 3.3621** 5.7618*** 0.8227 2.7485*** 
p-value 0.1043 0.0402 0.0005 0.4575 0.0002 
RDj 0.0004** 0.0003 -0.0005* 0.0006** -0.0002* 
p-value 0.0108 0.2579 0.0676 0.0122 0.0973 
HTEXj 0.0523 0.1284 0.1571** 0.0167 0.0130 
p-value 0.1764 0.1145 0.0213 0.7612 0.6818 
Adj. R2 0.8094 0.6170 0.6724 0.7269 0.8365 
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lost statistical significance. Nevertheless, the size of these coefficients is rather small yet. 
Interestingly, it is only possible to state that a one unit increase in the regressor HTEX affects 
positively Spanish imports of HS 3003 medicines, at a 5% significance level. A sensible 
explanation may be that R&D intensity is higher in the production of HS 3003 heading 
medicines.    
Subsequently, the mean ceteris paribus percentage variation in the predicted value of Spanish 
imports of the medical goods considered, when the value of Spanish exports of the same 
product is increased by 1%, has been analyzed. Moreover, the mean ceteris paribus 
percentage change in the predicted value of Spanish imports of medical goods when the 
value of the real effective exchange rate index of the exporting country is increased in 1% 
has been studied. However, it is not possible to state at a 10% significance level that the 
effect of these regressors on Spanish imports of either of the medical goods considered is 
different from zero. Moreover, a dummy variable for contiguity between Spain and the 
exporting country has initially been included but, since the results obtained do not appear to 
have economic sense, as contiguity seems to affect Spanish imports of medical goods 
negatively, it has been removed from the models. 
Results 
The model selection criteria will be Adjusted R2, which is an improvement of R2, as it 
penalizes the introduction of new regressors and enables the comparation of models 
including a different number of independent variables (Wooldridge, 2008). The higher the 
Adjusted R2, the better is the variation of the dependent variable explained by the regressors 
included in the model and, therefore, the better the model. Accordingly, evidence in Tables 
3, 4 and 5 suggests that Model 4 is the best model for explaining Spanish imports of 
medicines falling into HS heading 3004 (0.7368) and of those of PPE (0.8419), while Model 
5 is the preeminent model for describing total imports of medicines (0.8094) and imports of 
medicines under HS headings 3002 (0.6170) and 3003 (0.6724).  
Concerning Spanish imports of PPE, their predicted value seems to increase by 1.59% on 
average when the GDP of the exporting country rises by 1%, ceteris paribus. If the exporting 
country is a Member State to the EU, the predicted value of imports of PPE is 273% higher 
in mean than if it is an extra-EU country, keeping other variables unchanged. Other things 
equal, a 1% increase in the distance between Spain and its trading partner leads to a 1.09% 
decrease in the predicted value of imports of the goods in matter, while the latter decreases 
on average by 0.02% if the number of researchers in the exporting country is increased in 
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one person. Variations in these regressors explain 84.19% of the variations in the predicted 
value of Spanish imports of PPE.   
Regarding total Spanish medicine imports, other things equal, they seem to increase by 1.51% 
on average when the exporting country’s GDP is increased by 1%, and by 0.04% if the 
number of researchers in its trading partner rises in one person. In contrast, a 1% increase 
in the distance between Spain and the country of origin, ceteris paribus, leads to an average 
2.1% decrease in the predicted value of Spanish imports of medicines. It is not possible to 
state at a 10% significance level that EU membership by the exporting country and the share 
of high-technology exports of the latter affect the value of total Spanish imports of 
medicines. Variations in these regressors explain 80.94% of the changes in the predicted 
value of total medicine imports by Spain.  
A higher R&D activity associated with the pharmaceutical industry, as compared to PPE 
production in general, may explain why increases in the number of researchers in the 
exporting country affect total Spanish imports of medicines and PPE oppositely. Likewise, 
the higher MFN average tariff applied by the EU on PPE with respect to that applied on 
medicines, as well as the existence of non-tariff barriers to trade, may explain why EU 
membership by Spain’s trading partner appears to affect only PPE imports by Spain. 
Interestingly, some of the variables affecting the imports of various medicines also seem to 
diverge, as evidenced by the paragraphs that follow.  
With respect to Spanish imports of medicines under HS heading 3002, a ceteris paribus 1% 
increase in the GDP of the exporting country seems to increase their predicted value by 
2.1%, on average. Moreover, if the exporting country belongs to the EU, the predicted value 
of Spanish imports of HS 3002 medicines is expected to be 336% higher on average, other 
things equal, than if the exporting economy is an extra-EU state. Interestingly, it is not 
possible to claim at a 10% significance level that the distance between Spain and its trading 
partner, and the number of researchers and share of high technology exports in the latter, 
affect Spanish imports of the medicines under analysis. These variables explain 61.70% of 
the changes in the value of Spanish imports of products belonging to HS heading 3002.  
As for Spanish imports of HS 3003 medicines, other things equal, their predicted value 
appears to increase by 1.43% in mean when the GDP of the exporting country rises by 1%, 
and by 16% if the share of high technology exports by Spain’s trading partner increases in 
one unit. When the exporting country is an EU Member State, the value of imports of these 
medicines by Spain is 576% higher in mean, as compared to the case at which the exporting 
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economy is an extra-EU country, ceteris paribus. Counterintuitively, the value of Spanish 
imports of HS 3003 medicines seems to decrease on average by 0.05% if the number of 
researchers in the exporting country increases in one person, other things equal. It is not 
possible to state at a 10% significance level that increases in the distance between Spain and 
its trading partners affect the predicted value of Spanish imports of the products in matter. 
These regressors explain 67.24% of variations in the value of Spanish imports of HS 3003 
medicines.  
With regard to Spanish imports of medicines belonging to HS group 3004, their predicted 
value is found to increase by 1.7% on average when the GDP of its trading partner is 
augmented by 1%, ceteris paribus. Likewise, other things equal, their value seems to increase 
by 0.06% in mean if the number of researchers in the exporting country is augmented in one 
person. By contrast, a 1% increase in the distance between Spain and the country of origin 
decreases the predicted value of imports of the product in matter by 2.73%, ceteris paribus. 
Besides, it is not possible to claim, at a 10% significance level, that EU membership by the 
exporting country affects Spanish imports the cited goods. Changes in these variables explain 
73.68% of the variations in imports of medicines belonging to HS group 3004. 
6.3. Panel data analysis for 2007-2017 
A model for Spanish imports of medical goods in the period 2007-2017 is constructed in this 
section. Although a larger period of time was initially considered, the lack of data concerning 
relevant variables to the study for years before 2007 and after 2017 has led to a reduction in 
the time span analyzed. Models are based on the insights gained from the analysis performed 
in Section 6.2. Likewise, the software employed to that end is Gretl.  
The aim of this section is to determine whether the variables found as explicating Spanish 
imports of medical goods from OECD countries and China in 2016, do also explain 
variations in these trade flows during a period of time. Moreover, variables that are not found 
to affect Spanish imports of medical goods in 2016 are incorporated, so as to see if they 
affect trade over time. For this purpose, a panel data database has been constructed, 
consisting of thirty-six cross-sectional units, eight variables and eleven time periods (2007-
2017). The thirty-five OECD countries (excluding Spain) and China are referred to as cross-
sectional units, while the variables included are specified in the following subsection.  
6.3.1. Variables 
In addition to the regressors considered in the previous section, two new variables have been 
included: (i) The annual Real Effective Exchange Rate (REER) index (base year 2010) and 
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(ii) Spanish exports of medical goods to OECD countries and to China. The former has been 
added because changes in competitiveness may affect trade over time, whereas the latter may 
be of interest to the present analysis given the aforementioned intra-industry nature of trade 
in medicines. Regarding the cross-sectional data analysis for 2016, it is not possible to state 
at a 10% significance level that the effect of these regressors on Spanish imports of either of 
the medical goods considered is different from zero. Thus, they are included so as to check 
whether they affect variations in the value of Spanish imports of medical products over time.  
Data regarding Spanish exports of medical goods to OECD countries and to China, denoted 
as “EX”, has been obtained from DataComex. Since the unit of measurement in the database 
is current US$, they have been transformed into 2010 US$ by means of the Spanish GDP 
deflator retrieved from the World Development Indicators by World Bank.  
The REER index, which is denoted as “REER” and which has been retrieved from the 
International Financial Statistics database by the International Monetary Fund, is computed by 
dividing the nominal effective exchange rate (NEER) by a price deflator or cost index. The 
introduction of the annual REER, instead of considering the REER as of 31st December of 
the corresponding year, is due to the fact that it has been considered to be a better 
approximation to the values taken by the variable over the course of the year.  
6.3.2. Variable transformation and method 
Variables are checked for normality, with the purpose of including in the model variables 
with normally distributed errors. The Jarque-Bera (JB) Test is employed for this purpose. As 
previously explained, those variables reporting a p-value smaller than 0.05 in the JB Test are 
not considered to be normally distributed. The p-values resulting from the JB Test are 
presented in Table 4A in Annex 2 to the present study. According to the JB Test, imports 
and exports of medical goods, the GDP of Spain’s trading partners, the distance between 
Spain and the exporting country, the number of researchers in the country of origin, the 
share of high-technology exports in the latter, and the REER index regarding the exporting 
country do not follow a normal distribution. Thus, these variables will be included in 
logarithmic form in the models. 
Moreover, analyzing panel data involves a greater complexity that doing so with cross-
sectional data, as the former combines both cross-sectional and time series data. The most 
popular approaches for carrying analyses with this type of data are (i) Pooled OLS regression, 
(ii) Fixed effects model (FEM), and (iii) Random effects model (REM). Pooled OLS 
estimation refers to simple linear regression models employed for panel data, which do not 
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consider the effects over individuals and time (Gil-García & Puron-Cid, 2014). In contrast, 
FEM and REM take into account individual effects over time. Regarding FEM, it assumes 
that unobserved individual effects for each country are correlated with the independent 
variables included, while REM presumes that the unobserved individual heterogeneity is 
uncorrelated with explanatory variables (Wooldridge, 2008).  
By means of the Joint Significance and Breusch-Pagan Tests, it has been found out that both 
FEM and REM are preferred over the Pooled OLS approach for analyzing the models in 
this section. The null hypothesis in both tests, which claims that Pooled OLS regression is 
the preeminent approach, has been rejected at a 1% significance level for Model 6 and Model 
7, regarding all the different dependent variables, as shown in Table 6. Moreover, there is 
evidence supporting that the expected value of the unobserved effect contained in the error, 
given the explanatory variables, is constant. In fact, the null hypothesis in the Hausman Test 
states that the covariance between the explanatory variables and the error term is close to 
zero, which implies that REM is preferred over FEM. Given that, as evidenced in Table 6, it 
is not possible to reject the null hypothesis regarding this test at a 1% significance level in 
any case, neither for Model 6 nor for Model 7, the REM will be the one employed. 
Furthermore, the following assumptions are made: (i) No perfect linear relationship between 
regressors exists; (ii) the variance of the idiosyncratic error given the independent variables 
and the unobservable effect is constant; (iii) the variance of the individual effects given all 
regressors is constant; and (iv) the idiosyncratic errors, given independent variables and 
individual effects, are uncorrelated (Wooldridge, 2008).  
6.3.3. Analysis of Spanish imports of medical products in the period 2007-2017 
𝑙_𝐼𝑀𝑖𝑗𝑡 =  𝛼 + 𝛽1𝑙_𝐺𝐷𝑃𝑗𝑡 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝛽3𝐸𝑈𝑗𝑡 + 𝛽4𝑙_𝑅𝐷𝑗𝑡 + 𝛽5𝑙_𝐻𝑇𝐸𝑋𝑗𝑡 + 𝛽6𝑙_𝑅𝐸𝐸𝑅𝑗𝑡 + 𝑢𝑖𝑗𝑡 (Model 6) 
Model 6 is built on the basis of Model 5. According to the International Monetary Fund 
(2020), an increase in REER “indicates a loss in trade competitiveness”. β6 represents the 
mean ceteris paribus percentage variation in the predicted value of Spanish imports of the 
medical good in matter, when the value of the REER index of Spain’s trading partner is 
increased by 1%. Given that, an increase in the REER index of the exporting country would 
lead to more expensive imports by Spain, β6 is awaited to be negative.  
The interpretation of β1, β2 and β3 is identical to that provided for Model 3. As for β4, it 
denotes the ceteris paribus mean percentage change in the predicted value of Spanish imports 
of the medical goods considered, when the number of researchers in Spain’s trading partner 
increases by 1%. Similarly, β5 stands for the average percentage variation in the predicted 
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value of Spanish imports of medical products, caused by a ceteris paribus 1% increase in the 
value of the share of high-technology exports in the exporting country. From the reasonings 
provided in section 6.2.3, the following statements are straightforward: β1 is expected to be 
positive, β2 is expected to be negative, β3 is expected to be positive, β4 is expected to be 
positive, and β5 is expected to be positive. Table 6 below provides the coefficients obtained 
when running Model 6 in Gretl, their respective p-values, and the p-value related to the Joint 
Significance, Breusch-Pagan and Hausman tests. 
Table 6 
Estimation of Model 6 and 7 with 2007-2017 panel data (Random effects; Joint Significance, Breusch 
Pagan and Hausman tests) 
  Model 6 Model 7 
  Medicines PPE 
Medicines 
PPE 
Ind. V./ 
Dep. v.  Total 3002 3003 3004 Total 3002 3003 3004 
 
Constant -31.711*** -53.5748*** -23.7475* -27.8427*** -8.0957 -26.9806*** -54.1209*** -15.2694 -26.5729*** -7.8651 
p-value 0.0001 6.93E-05 0.0859 0.0027 0.1528 0.0012 5.53E-05 0.2775 0.0043 0.1474 
l_GDPjt 1.3561*** 1.8519*** 1.1370*** 1.3087*** 1.2136*** 0.9062*** 1.8287*** 0.7212** 1.1185*** 1.0698*** 
p-value 4.96E-11 1.97E-11 1.48E-05 4.59E-09 1.56E-19 1.00E-04 3.36E-10 1.18E-02 5.94E-06 3.34E-13 
l_Dij -1.6197*** -1.2049* -2.0224*** -1.7725*** -1.0413*** -1.4306** -1.1804* -1.8122** -1.6653*** -0.8837** 
p-value 0.0043 0.0903 0.0098 0.0034 0.0042 0.0116 0.0961 0.0207 0.0063 0.0117 
EUjt 0.9179 2.0712 1.004 0.6555 1.6096** 0.8266 2.0202 -0.234 0.6309 1.4213** 
p-value 0.37 0.1084 0.4176 0.5485 0.0143 0.4181 0.1162 0.8565 0.5644 0.0229 
l_RDjt 1.0993*** 0.8384* 0.425 1.127*** -0.2453 1.0717*** 0.8378* 0.3992 1.1656*** -0.2483 
p-value 0.0002 0.093 0.4036 0.0009 0.2374 0.0002 0.092 0.4311 0.0006 0.2169 
l_HTEXjt 1.4719*** 0.4343 1.1764* 1.1214*** 0.1795 1.5043*** 0.3838 1.0722* 1.1124*** 0.1574 
p-value 4.52E-09 0.4786 0.0674 0.0003 0.3387 8.53E-10 0.5317 0.0958 0.0003 0.3976 
l_REERjt 2.5887*** 3.8609** 3.2045* 2.4109*** -0.0113 2.4263*** 3.9644** 2.6893 2.2967*** -0.0385 
p-value 3.97E-05 0.0203 0.0632 0.0017 0.9812 8.01E-05 0.0186 0.1309 0.0027 0.9361 
l_EXijt      0.374*** 0.0415 0.3371*** 0.1816* 0.1734** 
p-value           8.97E-05 0.5564 0.0008 0.0701 0.0367 
Joint Sig. 1.87E-31 1.45E-13 1.89E-07 2.50E-20 2.29E-22 5.00E-35 2.69E-13 2.87E-08 2.23E-20 5.30E-26 
Breusch-P. 1.11E-145 1.19E-50 3.16E-23 6.57E-120 1.61E-110 2.60E-153 2.85E-50 8.48E-22 2.75E-124 8.95E-106 
Hausman 0.5705 0.6659 0.0274 0.6244 0.1420 0.742 0.4999 0.0208 0.8223 0.0678 
***p-value<0.01, **p-value <0.05, *p-value<0.1 
Source: own compilation based on data from Gretl.  
Model 6 in Table 6 evidences that a 1% ceteris paribus increment in the GDP of Spain’s 
trading partners increases the predicted value of Spanish imports of the all the medical goods 
considered, at a 1% significance level. With respect to a 1% increase in distance between 
Spain and the exporting country, other things equal, it causes negative changes in the 
predicted value of imports of all the medical goods. This effect is significant at a 10% 
significance level for imports of HS 3002 medicines, and at a 1% significance level in all other 
cases. Moreover, it is only possible to state that EU membership by the exporting country 
increases the predicted value of Spanish imports of PPE, at a 5% significance level.  
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A 1% increase in the number of researchers in the exporting country, ceteris paribus, causes 
an increase in the predicted value of total Spanish medicine imports (1% significance level), 
and of imports of medicines under HS headings 3002 (10% significance level) and 3004 (1% 
significance level). Likewise, a ceteris paribus 1% increment in the value of the share of high-
technology exports of the exporting county leads to increases in the predicted value of total 
Spanish imports of medicines and HS 3004 medicine imports (1% significance level), and of 
that of HS 3003 drugs (10% significance level). 
Increasing the value of the REER index of the exporting country by 1% appears to bring 
increases in the predicted value of total medicine imports (1% significance level) and of 
imports of medicines falling into HS 3002 (5% significance level), 3003 (10% significance 
level) and 3004 (1% significance level) headings. However, contrary to expectations, this 
effect is positive, meaning that a ceteris paribus 1% increase in the price of Spanish imports 
leads to a higher value of the latter. This may be explained by the low price-elasticity of 
demand of medicines in developed countries (Scherer, 2000; Otero García-Castrillón, 2006). 
𝑙_𝐼𝑀𝑖𝑗𝑡 =  𝛼 +  𝛽1𝑙_𝐺𝐷𝑃𝑗𝑡 + 𝛽2𝑙_𝐷𝑖𝑗 + 𝛽3𝐸𝑈𝑗𝑡 + 𝛽4𝑙_𝑅𝐷𝑗𝑡 + 𝛽5𝑙_𝐻𝑇𝐸𝑋𝑗𝑡 + 𝛽6𝑙_𝑅𝐸𝐸𝑅𝑗𝑡 + 𝛽7𝑙_𝐸𝑋𝑖𝑗𝑡 + 𝑢𝑖𝑗𝑡 
(Model 7) 
Model 7 adds Spanish exports of medical goods to OECD countries and China. β7 represents 
the ceteris paribus mean percentage variation in the predicted value of Spanish imports of 
medical products, caused by increasing the value of Spanish exports of the same medical 
good in 1%. β7 is expected to have a positive sign regarding Spanish medicine and PPE 
imports, because of the aforementioned intra-industry trade present in the pharmaceutical 
sector in the case of the former, and because it has been found that some of the most relevant 
trading partners of Spain coincide regarding imports and exports of PPE. The results 
obtained when running Model 7 in Gretl, including the coefficients, their respective p-values, 
and the p-value related to the Joint Significance, Breusch-Pagan and Hausman tests are 
displayed in Table 6 above. 
The conclusions for β1 in Model 7 are identical to those drawn in Model 6, except for that 
corresponding to imports of HS 3003 medicines, which has decreased its significance level 
to 5%. Table 6 suggests that a ceteris paribus 1% increase in the distance between Spain and 
its trading partners still leads to decreases in the predicted value of Spanish imports of 
medical goods, although statistical significance levels for the coefficients have changed: 10% 
for HS 3002 imports, 5% for total medicine imports and HS 3003 and PPE imports, and 1% 
for HS 3004 imports. The conclusions regarding the coefficients related to the regressors 
EU, logarithm of RD and logarithm of HTEX are the same as those provided in Model 6.  
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A 1% increase in the value of the REER index of the exporting country seems to increase 
the predicted value of total medicine imports (1% significance level) and of imports of 
medicines belonging to HS group 3002 (5% significance level) and 3004 (1% significance 
level). Nevertheless, it is not possible to state at a 10% significance level that the effect of 
the aforementioned increase on the predicted value of Spanish imports of HS 3003 medicines 
and PPE is different from zero. 
Increasing the value of total Spanish exports of medicines, of HS 3003 and HS 3004 
medicines and of those of PPE by 1%, ceteris paribus, seems to cause increases in the 
predicted value of Spanish imports of the same products. This effect is statistically significant 
at a 10% significance level for imports of HS 3004 medicines, at a 5% significance level for 
imports of PPE, and at a 1% significance level for total medicine imports and imports of HS 
3003 medicines. These results seem to support the view that intra-industry trade takes place 
regarding the pharmaceutical sector, except for HS 3002 medicines. Moreover, it may be 
plausible to explain bilateral flows of PPE by the existing Regional Trade Agreements 
between Spain and other countries18 considered in the analysis. 
Results  
With regard to the predicted value of Spanish imports of PPE, it increases by 1.07% in mean 
when the GDP of the exporting country grows in 1%, ceteris paribus. Moreover, imports of 
PPE seem to be 142% higher on average if Spain’s trading partner is an EU member, other 
things equal. Interestingly, a 1% increment of the value of Spanish exports of PPE to the 
considered countries, causes a 0.17% growth in the predicted value of Spanish imports of 
the same products, ceteris paribus. Distance between Spain and the exporting country 
appears to negatively affect the predicted value of Spanish imports of PPE, since the latter 
decreases by 0.88% when the cited distance grows in 1%, other things equal.  
With respect to the predicted value of total Spanish imports of medicines, it seems to increase 
by 0.91% in mean when the GDP of the exporting country rises in 1%, ceteris paribus. 
Likewise, it appears to increase in 1.07%, 2.43% and 0.37% when, other things equal, the 
number of researchers in the exporting country, the value of the REER index of the latter, 
or the Spanish exports of medicines are increased by 1%, respectively. Besides, a 1% increase 
in the value of the share of high-technology exports in Spain’s trading partner is found to 
lead to an average 1.5% increase in the predicted value of total medicine imports, ceteris 
 
18 EC Treaty, EU-Canada, EU-Chile, EU-Iceland, EU-Israel, EU-Japan, EU-Republic of Korea, EU-Mexico, 
EU-Norway, EU-Switzerland-Liechtenstein, EU-Turkey and EEA (World Trade Organization, 2020e). 
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paribus. By contrast, increasing the distance between Spain and its trading partner in 1%, 
other things equal, results in an average 1.43% decrease of the predicted value of Spanish 
imports of medicines.  
The fact that EU membership by the exporting country appears to only affect, positively, the 
predicted value of Spanish imports of PPE, may be explained by the presence of non-tariff 
barriers to trade, as well as by the 0% and 3.9% latest average MFN tariffs applied by the EU 
on medicines and PPE, respectively (World Trade Organization, 2020a). Presumably due to 
the low price elasticity of demand of medicines in developed countries (Scherer, 2000; Otero 
García-Castrillón, 2006), losses in trade competitiveness by the exporting country appear to 
increase only the forecasted value of Spanish medicine imports. Besides, the higher R&D 
activity and intensity attributed to the pharmaceutical industry, as compared to PPE 
production in general, may justify why increases in the number of researchers and in the 
value of the share of high-technology exports in the exporting country, seem to increase only 
the fitted value of total Spanish imports of medicines.  
Concerning the predicted value of imports of HS 3002 medicines, other things equal, it 
increases by 1.83% on average when the GDP of the country of origin of imports rises by 
1%. Increasing the number of researchers in the exporting country by 1% leads to an average 
0.84% increase in the predicted value of Spanish imports, ceteris paribus. Furthermore, a 1% 
growth in the value of the REER index of the exporting country, ceteris paribus, rises the 
predicted value of Spanish imports of HS group 3002 by 3.96% on average. Augmenting the 
distance between Spain and its trading partners in 1%, ceteris paribus, induces an average 
1.18% decrease in the predicted value of imports of these medicines.  
As for the forecasted value of imports of HS 3003 medicines, it is 0.72% higher in mean if 
the GDP of the Spanish trading partner is increased by 1%, other things equal. Besides, a 
1% increase in the value of the share of high-technology exports of the exporting country 
seems to rise the predicted value of HS 3003 heading imports by 1.07%, ceteris paribus. 
Similarly, when the value of Spanish exports of HS 3003 medicines grows by 1%, it appears 
to increase the value of Spanish imports of the same goods by 0.34% on average, other things 
equal. Moreover, a 1% ceteris paribus increase in the distance between Spain and the 
exporting country decreases the predicted value of Spanish imports of these medicines by 
1.81%, on average.  
Regarding Spanish imports of HS 3004 medicines, a ceteris paribus 1% increase in the GDP 
of the exporting country causes their predicted value to rise by 1.12% on average. If, other 
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things equal, the number of researchers in Spain’s trading partner goes up in 1%, or the value 
of the share of high-technology exports in the latter grows by 1%, the predicted value of 
Spanish imports of these medicines increases, on average, by 1.17% and 1.11%, respectively. 
Besides, a ceteris paribus 1% increase in the value of the REER index of the exporting 
country results in an average 2.3% increment in the forecasted value of Spanish imports. 
Moreover, when the value of Spanish exports of HS 3004 medicines is increased by 1%, 
ceteris paribus, the predicted value of Spanish imports of the same products is 0.18% higher 
in mean. By contrast, the predicted value of the cited imports decreases by 1.67%, on average, 
if the distance between Spain and the exporting country grows in 1%, ceteris paribus. 
The theoretical background of the Gravity Model, as represented by changes in the GDP of 
the exporting country and in the distance between Spain and the latter, seems to hold for all 
the medical goods considered in this analysis. Furthermore, increases in the value of Spanish 
exports of the product in matter appear to increase the predicted value of Spanish imports 
of all the medical goods considered, except for those of HS 3002 medicines. This may be 
explained by the importance of intra-industry trade in the pharmaceutical sector, as well as 
by the Regional Trade Agreements in which Spain participates. Nevertheless, this analysis 
suggests that other variables determining total Spanish imports of medicines and PPE, as 
well as those of various medicines, appear to differ. 
7. CONCLUSIONS 
The aims of the present paper are (i) to describe the context in which international trade in 
medical products takes place, and (ii) to analyze the determinants of Spanish imports of these 
goods from OECD countries and China. Concerning medical products, pharmaceutical 
products and personal protective equipment (PPE) are covered.  
Regarding the first objective, the pharmaceutical industry has high R&D investment rates 
and intensity. Intra-industry trade is very significant in this sector, while market concentration 
is high, as well as geographical concentration and internationalization. Besides, the demand 
of medicines in developed countries has a low price elasticity. Medicines have a large strategic 
value from the health and industrial perspectives, and they are the medical products with the 
lowest MFN tariff applied by WTO members. However, due to their effects on health, non-
tariff barriers to trade on medicines are significant, both globally and inside the EU. As for 
PPE, its production involves low profit margins, and takes place mainly in Asia. Even if PPE 
is not as regulated as medicines, it is subject to strong regulations. Furthermore, the average 
MFN tariff applied by WTO members on PPE is five times greater than that on medicines. 
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It is worth of mention that trade in medical products has acquired considerable importance 
recently, due to Covid-19, as the latter has increased their global demand. In this context, 
some nations have applied protectionist measures to trade in medical products, while other 
countries have advocated for removing existing trade barriers on the cited goods.  
For the second objective, two econometric analyses with 2016 cross-sectional data and 2007-
2017 panel data are performed, for Spanish imports of medical goods from OECD countries 
and China. Both analyses suggest that certain variables explaining total Spanish imports of 
medicines and PPE differ, as well as those determining Spanish imports of distinct medicines. 
Results seem to capture differences in the market for each product.  
With respect to 2016 data, it appears that Spanish imports of all the goods considered are 
affected positively by increases in the exporting country’s GDP. Likewise, augmenting the 
distance between Spain and its trading partner seems to affect negatively total Spanish 
imports of medicines and PPE. Increases in the number of researchers in the exporting 
country appear to affect positively total medicine imports and negatively PPE imports by 
Spain. Besides, EU membership by Spain’s trading partners seems to increase the predicted 
value of Spanish PPE imports. Concerning imports of various medicines by Spain in 2016, 
increases in the distance between Spain and its trading partners seem to negatively affect HS 
3004 medicine imports, while EU membership by the exporting country appears to increase 
the value of imports of HS 3002 and 3003 medicines. Moreover, increases in the number of 
researchers in the exporting country seem to negatively affect imports of HS 3003 medicines 
and positively HS 3004 medicine imports. Finally, augmenting the share of high-technology 
exports of Spain’s trading partner is found to affect, positively, HS 3003 medicine imports.  
Results from the 2007-2017 analysis suggest that, over time, the Gravity Model holds for 
Spanish imports of all the goods studied. Both, total Spanish imports of medicines and PPE, 
seem to be affected positively by increases in the value of Spanish exports of the same goods. 
Moreover, EU membership by the exporting country appears to only affect Spanish imports 
of PPE, positively. Furthermore, increases in the number of researchers in the exporting 
country and in the value of the share of high-technology exports in the latter, seem to affect 
positively Spanish imports of medicines solely. Besides, losses in trade competitiveness by 
Spain’s trading partners appear to positively affect Spanish medicine imports. As for Spanish 
imports of various medicines, increases in the number of researchers in the exporting country 
and losses in trade competitiveness by the latter, are found to increase the predicted value of 
HS 3002 and 3004 medicine imports, exclusively. Moreover, increments in the value of the 
share of high-technology exports by the exporting country, as well as in the value of Spanish 
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exports of the same goods to the latter, seem to do so for Spanish imports of medicines 
under HS 3003 and 3004 headings.  
Note that the main limitation faced by this paper is the unavailability of data for many years 
for central regressors to the analysis, which leads to studying a short period of time. 
Additionally, a similar econometric analysis has been performed for finding out the 
determinants of Spanish exports of medical goods to OECD countries and China. However, 
it has not been included in the paper, given that the results obtained do not appear to provide 
insights consistent with the industry and regulatory characteristics of the cited products. 
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9. ANNEXES 
9.1. Annex 1 
Table 1A 
Indicators of the Structure of Pharmaceutical Industry. World largest 50 companies by sales (in billions of 
US$) (2018) 
  
Rank Country Sales  
R&D 
expenditure 
R&D/ 
Sales 
Market 
Share 
Concentration 
index1 
1 Pfizer US 45302 7962 18% 6,66% 6,66% 
2 Roche Switzerland 44552 9803 22% 6,54% 13,20% 
3 Novartis Switzerland 43481 8154 19% 6,39% 19,59% 
4 Johnson & Johnson US 38815 8446 22% 5,70% 25,29% 
5 Merck & Co US 37353 7908 21% 5,49% 30,78% 
6 Sanofi France 35121 6227 18% 5,16% 35,94% 
7 AbbVie US 32067 5093 16% 4,71% 40,65% 
8 GlaxoSmithKline England 30645 4987 16% 4,50% 45,15% 
9 Amgen US 22533 3657 16% 3,31% 48,46% 
10 Gilead Sciences US 21677 3897 18% 3,18% 51,64% 
11 Bristol-Myers Squibb US 21581 5131 24% 3,17% 54,81% 
12 AstraZeneca England 20671 5266 25% 3,04% 57,85% 
13 Eli Lilly US 19580 4993 26% 2,88% 60,73% 
14 Bayer Germany 18221 3417 19% 2,68% 63,40% 
15 Novo Nordisk Denmark 17726 2347 13% 2,60% 66,01% 
16 Takeda Japan 17427 3012 17% 2,56% 68,57% 
17 Celgene US 15238 4084 27% 2,24% 70,81% 
18 Shire Ireland 14993 1608 11% 2,20% 73,01% 
19 Boehringer Ingelheim Germany 14834 3206 22% 2,18% 75,19% 
20 Allergan US 14700 1575 11% 2,16% 77,35% 
21 Teva Pharma. Ind. Israel 13122 1213 9% 1,93% 79,28% 
22 Mylan US 11144 586 5% 1,64% 80,91% 
23 Astellas Pharma Japan 11036 1909 17% 1,62% 82,53% 
24 Biogen US 10887 2587 24% 1,60% 84,13% 
25 CSL Australia 8270 724 9% 1,21% 85,35% 
26 Daiichi Sankyo Japan 7033 1888 27% 1,03% 86,38% 
27 Merck KGaA Germany 7001 1928 28% 1,03% 87,41% 
28 Otsuka Holdings Japan 5726 1863 33% 0,84% 88,25% 
29 UCB Belgium 5138 1371 27% 0,75% 89,01% 
30 Les Laboratoires Servier France 5103 N/A 0% 0,75% 89,76% 
31 Bausch Health Companies Canada 4631 413 9% 0,68% 90,44% 
32 Eisai Japan 4531 1309 29% 0,67% 91,10% 
33 Abbott Laboratories US 4422 184 4% 0,65% 91,75% 
34 Fresenius Germany 4328 631 15% 0,64% 92,39% 
35 Sun Pharmaceutical Ind. India 4222 321 8% 0,62% 93,01% 
36 Grifols Spain 4154 284 7% 0,61% 93,62% 
37 Alexion Pharmaceuticals US 4130 704 17% 0,61% 94,22% 
38 Regeneron Pharmaceuticals US 4106 2186 53% 0,60% 94,83% 
39 Chugai Pharmaceutical Japan 3649 855 23% 0,54% 95,36% 
40 
Sumitomo Dainippon 
Pharma Japan 3543 776 22% 0,52% 95,88% 
41 Menarini Italy 3313 N/A 0% 0,49% 96,37% 
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42 Sino Biopharmaceutical Hong Kong 3142 339 11% 0,46% 96,83% 
43 Vertex Pharmaceuticals US 3038 1292 43% 0,45% 97,28% 
44 Endo International Ireland 2947 141 5% 0,43% 97,71% 
45 Mitsubishi Tanabe Pharma Japan 2913 755 26% 0,43% 98,14% 
46 Ipsen France 2628 357 14% 0,39% 98,52% 
47 Jiangsu Hengrui Medicine China 2570 334 13% 0,38% 98,90% 
48 Mallinckrodt Ireland 2543 361 14% 0,37% 99,28% 
49 STADA Arzneimittel Germany 2467 85 3% 0,36% 99,64% 
50 Ferring Pharmaceuticals US 2461 357 15% 0,36% 100,00% 
Source: Own compilation based on data from Christel (2019). 
 
9.2. Annex 2 
    Table 2A 
    Results of Jarque-Bera test for normality19 (cross-sectional data 2016) 
  
 
 
 
 
 
 
 
   Source: Own compilation based on data from Gretl.  
 
 
 
 Table 3A 
White’s test for heteroskedasticity p-values (2016 cross-sectional data) 
 
 
 
 
 
Source: Own compilation based on data from Gretl.  
 
19 No JB Test p-value available for GDPi. 
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     Table 4A 
     Results for Jarque-Bera test for normality (panel data 2007-2017) 
 
 
 
 
 
 
 
                    Source: Own compilation based on data from Gretl. 
 
 
